



## Adempas Prior Authorization Request

## Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect<sup>®</sup> 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: Patient's ID: Physician's Name: Specialty: Physician Office Telephone: Request Initiated For:		Patient's Date of Birth:  NPI#: Physician Office Fax:
1.	What is the diagnosis?  ☐ Chronic thromboembolic pulmonary hyperter ☐ Pulmonary arterial hypertension (PAH) ☐ Other	
2.	What is the ICD-10 code?	_
3.	Is the request for continuation of therapy with A	dempas? ☐ Yes ☐ No If No, skip to #5
4.	Is the patient currently receiving Adempas through Yes $\square$ No If No, no further questions	igh samples or a manufacturer's patient assistance program?
5.	2 (BMPR2); Activin receptor-like kinase type 1 telangiectasia), Smad 9, caveolin-1 (CAV1), pot Unknown] C) Drug- and toxin-induced D) Associated with hypertension; Congenital heart diseases; Schister	
	inflow/outflow tract obstruction and congenital ☐ WHO Group 3. Pulmonary Hypertension Of A) Chronic obstructive pulmonary disease B) I	n C) Valvular disease D) Congenital/acquired left heart cardiomyopathies. wing to Lung Disease and/or Hypoxia Interstitial lung disease C) Other pulmonary diseases with eep-disordered breathing E) Alveolar hypoventilation
Note:	This fax may contain medical information that is privileged and con	fidential and is solely for the use of individuals named above. If you are not the intended

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please

immediately notify the sender by telephone and destroy the original fax message. Adempas SGM - 10/2016

	□ WHO Group 4. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) □ WHO Group 5. Pulmonary Hypertension with Unclear Multifactorial Mechanisms A) Hematologic disorders: Chronic hemolytic anemia, myeloproliferative disorders, splenectomy B) Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis C) Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders D) Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH.			
6.	Has PAH been confirmed by right heart catheterization? ☐ Yes ☐ No			
7.	What is the pretreatment mean pulmonary arterial pressure at rest?	mmHg		
8.	What is the pretreatment capillary wedge pressure? mml	Нg		
9.	What is the pretreatment pulmonary vascular resistance?	Wood units		
Complete the following section based on the patient's diagnosis.				
	ection A: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)  0. Does the patient have recurrent or persistent CTEPH after pulmonary endarterectomy?  If Yes, no further questions □ Yes □ No			
11.	Does the patient have inoperable CTEPH? ☐ Yes ☐ No			
12.	2. Has CTEPH been confirmed by pulmonary angiography, computed tomography (CT) angiography, or magnetic resonance imaging (MRI) angiography?    Yes   No			
I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.				
<b>X</b>				
Pre	escriber or Authorized Signature	Date (mm/dd/yy)		